^
Association details:
| Biomarker: | EGFR mutation + EGFR amplification |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | EGFR inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
67P-Distinct concomitant genetic alterations in EGFR-mutant non-small cell lung cancer patients with brain metastases
Published date:
03/23/2022
Excerpt:
A total of 2657 NSCLC patients with brain metastases were screened and 737 harboring EGFR mutation, among 73 patients with NGS data, all receiving EGFR TKI treatment...Concomitant genetic alterations were significantly associated with reduced OS (23.2 months vs NR, P= 0.016). Especially, TP53 mutation (HR = 1.8, 95%CI:1.0-3.2) and EGFR amplification (HR = 2.5, 95% CI:1.2-5.6) were associated with significantly worse OS....
DOI:
https://doi.org/10.1016/j.annonc.2022.02.076
Source:
Title:
EGFR amplification is a putative resistance mechanism for NSCLC–LM patients with TKI therapy and is associated with poor outcome
Published date:
08/01/2022
Excerpt:
A multivariable Cox proportional hazard regression model showed that EGFR amplification was an independent prognostic factor for poorer OS (8.3 vs. 15 months; p = 0.017)....OS was significantly shorter in patients with than those without EGFR amplification (p = 0.017). Moreover, patients with both EGFR and a co-mutation of amplification were more likely to have a poorer KPS score (p = 0.021) and a higher CSF pressure (p = 0.0067) than patients with a mutation but without EGFR amplification...EGFR gene amplification was associated with lower KPS and poorer OS. These findings suggested that EGFR gene amplification may be responsible for the resistance of NSCLC–LM patients to EGFR-TKIs...
DOI:
https://doi.org/10.3389/fonc.2022.902664
